Agro Biotech Accélérateur (ABA) was created by INRA and Seventures Partners, a leading French investor in venture capital, at the end of 2008. Daniel Burtin has recently replaced Pascal Azadian at the head of ABA that is dedicated to providing top INRA research laboratory projects with industrialization potential with the resources to create startups for project commercialization. Appointed last December, Daniel Burtin's first assignment was to complete the selection audits of the projects that will receive ABA support and ensure the incubation and maturing of the facility's first two projects.
One project is the outcome of research by the scientists on the Lactic Acid Bacteria and Useful Surface Proteins team, MICALIS Unit, INRA Jouy-en-Josas Center. Project goal is to meet the ever-changing demands of industry operators, retailers and consumers for the greater safety and longevity of fresh meat. The first tests run for the project led to substantial improvements in the preservation of products such beef carpaccio, which is usually sold in the the ultra-fresh section at large retailers, by guaranteeing the very strict control of spoilage flora while preserving the typical aspect of the products.
The other project that is being incubated at ABA is on the border between probiotics and pharmaceutical products. Dr. Annick Bernalier's team at the Microbiology Laboratory, Theix INRA Center, has established a correlation between certain anomalies of intestinal flora called Microbiome and irritable bowel syndrome (IBS). The discovery was followed by different in vitro and in vivo studies that clear the way for therapeutic approaches. Under ABA management, clinical trials will be run on humans to validate the beneficial effects of new pharmaceutical compounds on patients suffering from acute and recurrent intestinal pain. The findings should lead to creating a business and commercializing the products resulting from the research.